Predict your next investment

EVOQ Therapeutics company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer


Convertible Note | Alive

Total Raised


Last Raised

$50K | 3 yrs ago

About EVOQ Therapeutics

EVOQ Therapeutics develops vaccines that produce robust anti-tumor immunity against new tumor epitopes while broadening T-cell responses against multiple tumor epitopes.

EVOQ Therapeutics Headquarter Location

534 Glendale Circle

Ann Arbor, Michigan, 48103,

United States

Latest EVOQ Therapeutics News

BRIEF—EVOQ signs licensing deal with Amgen

Jan 18, 2021

USA-based EVOQ Therapeutics has entered into a license and collaboration agreement with biotech major Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the accord, Amgen and EVOQ will collaborate on pre-clinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes innovative medicines, including Otezla (apremilast), which it picked up from Celgene after it merged with Bristol Myers Squibb in 2019. It also has Enbrel (etanercept), and biosimilar products, such as Amgevita, a biosimilar to Humira (adalimumab)) and Avsola, a biosimilar to Remicade.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.